Skip to main content
. 2019 Oct 2;294(45):16908–16917. doi: 10.1074/jbc.RA119.011009

Figure 10.

Figure 10.

MA promotes cisplatin-induced acute kidney injury through inhibiting FTO-mediated m6A modification. Treatment with cisplatin reduced FTO expression and increased the m6A levels in kidneys, which leads to the up-regulation of p53. MA aggravated the renal damages in cisplatin-treated kidneys through p53-mediated apoptosis pathways (the Bax/Bcl-2 and Caspase3 pathways).